Article Sidebar

Submitted
Apr 22, 2021
Published
Apr 22, 2021
Download
PDF
Statistic
Read Counter : 34 Download : 23

Main Article Content

Abstract

BACKGROUND


Cardiovascular disease develops 7 to 10 years later in women than in men and is still the major cause of death in women. The risk of heart disease in women is often underestimated due to the misperception that females are ‘protected’ against cardiovascular disease.


AIM


To determine 10 year cardiovascular risk in hypertensive patients of either sex with emphasis on specific risk factors predisposing to morbidity and mortality from cardiovascular disease in both sexes.


MATERIALS AND METHODS


This cross-sectional observational study was conducted in the Cardiology outpatient department (OPD) at Rajindra Hospital, Patiala. A total of 150 patients were included in the study. The data pertaining to four risk factors-ages, smoking history, blood pressure and serum cholesterol level was collected from all the patients. Data collected was used to calculate 10 year risk of morbidity and mortality from cardiovascular disease by using Framingham Risk Score.


RESULTS


In the present study patients were in the age group of 35-60 years and out of 150 patients 85 were females and 65 were males. It was observed that serum cholesterol was in borderline range in 46.15% of females and 29.4% of males whereas raised serum cholesterol levels were observed in 23.5% females and 15.38% males. 52.9% of females and 92.3% of males were having stage 1 hypertension and stage 2 hypertension was risk factor in 47.05% of females and 23.07% of males. Smoking history was present in 4.7% of females and 61.5% of males. According to Framingham Heart Score, 8.2% of females and 26.15% males were in low risk category (calculated risk<10%). Moderate risk (calculated risk between 10-20%) was observed in 35.29% females and 33.84% males whereas high risk (calculated score more than 20%) was observed in 56.4% females and 55.38% males.

Keywords

Hypertension cholesterol smoking and Framingham Heart Score

Article Details

How to Cite
Payal preet, Anita K. Gupta, & Harcharan Singh. (2021). Gender based assessment of 10 year cardiovascular risk in hypertensive patients. International Journal of Research in Pharmacology & Pharmacotherapeutics, 4(3), 295-301. https://doi.org/10.61096/ijrpp.v4.iss3.2015.295-301
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. [1]. Towfighi A, Zheng L, Ovbiagele B. Sex-specific trends in midlife coronary heart disease risk and prevalence. Arch Intern Med. 2009; 169:1762-6.
  2. [2]. Prescott E, Hippe M, Schnohr P, Hein HO, Vestbo J. Smoking and risk of myocardial infarction in women and men: longitudinal population study. BMJ. 1998; 316:1043-7.
  3. [3]. Ossewaarde ME, Bots ML, Verbeek AL, et al. Age at menopause, cause-specific mortality and total life expectancy. Epidemiology. 2005; 16:556-62.
  4. [4]. Bairey Merz CN, Johnson BD, Sharaf BL, et al. Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the NHLBI-sponsored WISE study. J Am Coll Cardiol. 2003; 41:413-9.
  5. [5]. Sutton-Tyrell K, Lassila HC, Meilahn E, Bunker C, Matthews KA, Kuller LH. Carotid atherosclerosis in premenopausal and postmenopausal women and its association with risk factors measured after menopause.Stroke. 1998; 29:1116-21.
  6. [6]. Hochman JS, Tamis, JE, Thompson TD, et al. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. N Engl J Med. 1999; 341:226-32.
  7. [7]. Vaccarino V, Parsons L, Every NR, Barron HV, Krumholz HM. Sex-based differences in early mortality after myocardial infarction. National Registry of Myocardial Infarction 2 Participants. N Engl J Med.1999; 341:217-25.
  8. [8]. Grundtvig M, Hagen TP, German M, Reikvam A. Sex-based differences in premature first myocardial infarction caused by smoking: twice as many years lost by women as by men. Eur J Cardiovasc Prev Rehab.2009; 16:174-9.
  9. [9]. Vanhoutte PM, Shimokawa H, Tang EHC, Feletou M. Endothelial dysfunction and vascular disease. Acta Physiol. 2009; 196:193-222.
  10. [10]. Kip KE, Marroquin OC, Kelley DE, et al. Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women. Circulation. 2004; 109:706-13.
  11. [11]. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006; 332:73-8.
  12. [12]. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995; 25:305-13.
  13. [13]. Dubey RK, Oparil S, Imthurn B, Jackson EK. Sex hormones and hypertension. Cardiovasc Res.2002; 53:688-708.
  14. [14]. Barton M, Meyer MR. Postmenopausal hypertension. Mechanisms and therapy. Hypertension. 2009; 54:1118.
  15. [15]. Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345:1291-7.
  16. [16]. Maas AHEM, Franke HR. Women’s health in menopause with a focus on hypertension. Neth Heart J.2009; 17:69-73.
  17. [17]. Ikeda H, Inoue T, Uemura S, Kaibara R, Tanaka H, Node K. Effects of candesartan for middle-aged and elderly women with hypertension and menopausal-like symptoms. Hypertens Res. 2006; 29:1007-12.
  18. [18]. Gast G-CM, Grobbee DE, Pop VJM, Keyzer JJ, Wijnands-van Gent CJM, Samsioe GN; et al. Menopausal complaints are associated with cardiovascular risk factors. Hypertension. 2008; 51:1492-8.
  19. [19]. Matthews KA, Meilahn EN, Kuller LH, Kelsey SF, Caggiula AW, Wing RR. Menopause and risk factors for coronary heart disease. N Engl J Med. 1989; 321:641-6.
  20. [20]. Abbey M, Owen A, Suzakawa M, Roach P, Nestel PJ. Effects of menopause and hormone replacement therapy on plasma lipids, lipoproteins and LDL-receptor activity. Maturitas. 1999; 33:259-69.
  21. [21]. Kannel WB, Castelli WP, Gordon T, McNamar PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham Study. Ann Intern Med. 1971; 74:1-12.
  22. [22]. Baigent C, Keech A, Kearny PM, Blackwell L, Buck G, Pollicino C, et al. Cholesterol Treatment Trialists collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90.056 participants in 14 randomised trials of statins. Lancet. 2005; 366:1267-78.
  23. [23]. Mizuno K, Nakaya N, Ohashi Y, Tajima N, Kushiro T, Teramoto T, et al. Usefulness of pravastatin in primary prevention of cardiovascular events in women. Analysis of the management of elevated cholesterol in the primary prevention group of adult Japanese (MEGA-study). Circulation. 2008; 117:494-502.
  24. [24]. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359:2195-207.
  25. [25]. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer later in life: systematic review and meta-analysis. BMJ. 2007; 335:974-85.
  26. [26]. McDonald SD, Malinowski A, Zhou Q, Yusuf S, Devereaux PJ. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analysis. Am Heart J. 2008; 156:918-30.
  27. [27]. Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet. 2009; 373:1773-9.
  28. [28]. Mosca L, Banka CL, and Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation. 2007; 115:1481-501.